TRXB NASDAQ
TRex Bio Inc.
1W: -5.1%
YTD: +3.3%
$13.79
-0.08 (-0.58%)
After Hours: $13.97 (+0.19, +1.34%)
Credit Risk of going bust: not rated Bonds: none of note held by US funds details ▾
Not rated: no recent balance sheet.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider+$2.5M
Congress—
ETF Holdings—
Key Statistics
Market Cap$114.9M
52W Range13.21-16.56
Volume42,864
Avg Volume232,690
Beta0.00
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOMarion Johnston Erwin
Employees60
SectorHealthcare
IndustryMedical - Pharmaceuticals
IPO Date2026-10-09
Websitetrex.bio
269 E. Grand Ave., Suite 300
South San Francisco, CA 94080
US
South San Francisco, CA 94080
US
About TRex Bio Inc.
Trex Bio, Inc. engages in the manufacture of immunotherapies for autoimmune and inflammatory diseases. It focuses on studying the regulation of tissue inflammation to develop breakthrough medicines. The company was founded by Houman Ashrafian, Adil Daud, Wilson Liao, Diane Mathis, Drew Pardoll, Michael Rosenblum, Alison Simmons, and Jim Wells in May 24, 2018 and is headquartered in South San Francisco, CA.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Alexandria Venture I | C-Conversion | 1,167,930 | — | 2026-10-13 |
| Alexandria Venture I | P-Purchase | 178,571 | $14.00 | 2026-10-13 |
| Alexandria Venture I | C-Conversion | 1,033,541 | — | 2026-10-13 |
| Alexandria Venture I | C-Conversion | 3,480,387 | — | 2026-10-13 |
| ELI LILLY & Co | 0 | — | 2026-10-08 |